Life Science Big News Roundup: Biocure Signs a Collaboration Agreement with Y Biologics; PreveCeutical Provides Update on the Dual Gene Therapy Program; Lexaria Partners with Altria to Fund Research and Development of DehydraTECH(tm) Technology
In case you missed it, here is this week’s life science big news roundup.
Kura Oncology Reports Clinical Activity of Tipifarnib in Subsets of Pancreatic Cancer Associated with High CXCL12 Expression
Kura Oncology (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, reported new findings identifying...
Precision Therapeutics Receives $1,370,000 Investment from CEO and Director, Carl Schwartz
Precision Therapeutics (NASDAQ:AIPT) announced that its chief executive officer and director, Carl Schwartz, has made an additional investment of $1,000,000...
TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study
Tyme Technologies (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial...
AVROBIO Announces Acceptance of Investigational New Drug (IND) Application
AVROBIO (NASDAQ:AVRO) a Phase 2 clinical-stage gene therapy company, today announced that its investigational gene therapy candidate for cystinosis, AVR-RD-04, is cleared...
Bavarian Nordic Announces Exercise of USD 44 Million Option by the U.S. Government
Bavarian Nordic (OMX:BAVA,OTC:BVNRY) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA) have exercised another option under...
Immunomedics Receives Complete Response Letter From FDA for Sacituzumab Govitecan Biologics License Application
Immunomedics (NASDAQ:IMMU) a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced it has received a Complete Response Letter...